FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013558407> ?p ?o ?g. }

• W3013558407 abstract "Background Standard-of-care (SoC) for systemic lupus erythematosus (SLE) includes use of glucocorticoids, antimalarials, immunosuppressive agents and biologics. Selection of drug(s) for each unique patient is mainly based on the severity of afflicted organ system(s), the global disease activity, and serological status (i.e. anti-dsDNA and complement levels). Development of lupus nephritis (LN) during treatment with belimumab, an inhibitor of soluble B cell activating factor (BAFF), has previously been reported.1,2 This observational follow-up study, utilising data from several university centers, aimed to evaluate the real-life frequency of LN during belimumab treatment. Methods At the Swedish university centers in Linkoping, Lund, Stockholm and Uppsala, as well as in Leeds, UK, all patients who received belimumab from 2011 until 2018 (N=95; 52% anti-dsDNA positive, 60% low complement) were followed longitudinally in regional observational study programmes (median follow up: 13 months). In cases of a suspected incident LN or LN relapse/worsening, renal biopsy was performed. As a comparator, non-renal SLE cases not exposed to belimumab (N=107; 40% anti-dsDNA positive, 47% low complement) were encompassed; these patients were followed for a median time of 132 months and incident LN cases were registered. Total follow-up and time to LN was calculated for each group and was utilised in Cox regression analysis. Results We observed 6/66 cases (9.1%) of biopsy-proven de novo LN (4/6 were class III or IV) in the non-renal SLE belimumab-treated group after a median follow-up time of 7.4 (IQR: 2.7–22.2) months, and 2/29 cases (6.9%) of LN relapse after 1 and 9 months in the belimumab-treated group with historical but quiescent LN at treatment initiation. In the comparator group, 2/107 cases (1.9%) of de novo LN (1 class III, 1 class IV) were observed after 21 and 50 months. Cox regression analysis revealed increased risk and/or shorter time to de novo LN in non-renal patients who received belimumab compared with non-renal SLE comparators (HR: 17.4; 95% CI: 2.7–110.8; P=0.002). A Kaplan-Meier graph is attached. Conclusions This observational study indicates that addition of belimumab to SoC may not prevent LN among patients with ongoing non-renal SLE disease activity. Selection of cases suitable for belimumab based on serological activity could be troublesome as these patients may be at high risk of developing LN.3 The effects of BAFF inhibition on different lymphocyte subsets which may contribute to LN susceptibility have yet to be explored. Identification of predictors of LN development among belimumab-treated patients is merited. References Sjowall C, Coster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol 2014;43:428–30. Staveri C, Karokis D, Liossis SC. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum 2017;46:788–790. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343–49." @default.
• W3013558407 created "2020-04-03" @default.
• W3013558407 creator A5002914719 @default.
• W3013558407 creator A5023290270 @default.
• W3013558407 creator A5028042265 @default.
• W3013558407 creator A5037276492 @default.
• W3013558407 creator A5055854855 @default.
• W3013558407 creator A5059152300 @default.
• W3013558407 creator A5062686406 @default.
• W3013558407 creator A5077255003 @default.
• W3013558407 creator A5086543859 @default.
• W3013558407 creator A5087055086 @default.
• W3013558407 date "2020-03-01" @default.
• W3013558407 modified "2023-10-16" @default.
• W3013558407 title "P137 De novo lupus nephritis during belimumab treatment" @default.
• W3013558407 doi "https://doi.org/10.1136/lupus-2020-eurolupus.181" @default.
• W3013558407 hasPublicationYear "2020" @default.
• W3013558407 type Work @default.
• W3013558407 sameAs 3013558407 @default.
• W3013558407 citedByCount "1" @default.
• W3013558407 countsByYear W30135584072020 @default.
• W3013558407 crossrefType "proceedings-article" @default.
• W3013558407 hasAuthorship W3013558407A5002914719 @default.
• W3013558407 hasAuthorship W3013558407A5023290270 @default.
• W3013558407 hasAuthorship W3013558407A5028042265 @default.
• W3013558407 hasAuthorship W3013558407A5037276492 @default.
• W3013558407 hasAuthorship W3013558407A5055854855 @default.
• W3013558407 hasAuthorship W3013558407A5059152300 @default.
• W3013558407 hasAuthorship W3013558407A5062686406 @default.
• W3013558407 hasAuthorship W3013558407A5077255003 @default.
• W3013558407 hasAuthorship W3013558407A5086543859 @default.
• W3013558407 hasAuthorship W3013558407A5087055086 @default.
• W3013558407 hasBestOaLocation W30135584071 @default.
• W3013558407 hasConcept C126322002 @default.
• W3013558407 hasConcept C159654299 @default.
• W3013558407 hasConcept C170286685 @default.
• W3013558407 hasConcept C203014093 @default.
• W3013558407 hasConcept C23131810 @default.
• W3013558407 hasConcept C2775934546 @default.
• W3013558407 hasConcept C2776912625 @default.
• W3013558407 hasConcept C2778453870 @default.
• W3013558407 hasConcept C2779134260 @default.
• W3013558407 hasConcept C2779561371 @default.
• W3013558407 hasConcept C2779912601 @default.
• W3013558407 hasConcept C2780091579 @default.
• W3013558407 hasConcept C2781087799 @default.
• W3013558407 hasConcept C2781205201 @default.
• W3013558407 hasConcept C71924100 @default.
• W3013558407 hasConcept C90924648 @default.
• W3013558407 hasConceptScore W3013558407C126322002 @default.
• W3013558407 hasConceptScore W3013558407C159654299 @default.
• W3013558407 hasConceptScore W3013558407C170286685 @default.
• W3013558407 hasConceptScore W3013558407C203014093 @default.
• W3013558407 hasConceptScore W3013558407C23131810 @default.
• W3013558407 hasConceptScore W3013558407C2775934546 @default.
• W3013558407 hasConceptScore W3013558407C2776912625 @default.
• W3013558407 hasConceptScore W3013558407C2778453870 @default.
• W3013558407 hasConceptScore W3013558407C2779134260 @default.
• W3013558407 hasConceptScore W3013558407C2779561371 @default.
• W3013558407 hasConceptScore W3013558407C2779912601 @default.
• W3013558407 hasConceptScore W3013558407C2780091579 @default.
• W3013558407 hasConceptScore W3013558407C2781087799 @default.
• W3013558407 hasConceptScore W3013558407C2781205201 @default.
• W3013558407 hasConceptScore W3013558407C71924100 @default.
• W3013558407 hasConceptScore W3013558407C90924648 @default.
• W3013558407 hasLocation W30135584071 @default.
• W3013558407 hasOpenAccess W3013558407 @default.
• W3013558407 hasPrimaryLocation W30135584071 @default.
• W3013558407 hasRelatedWork W11221851 @default.
• W3013558407 hasRelatedWork W18264973 @default.
• W3013558407 hasRelatedWork W18792989 @default.
• W3013558407 hasRelatedWork W3431460 @default.
• W3013558407 hasRelatedWork W475345 @default.
• W3013558407 hasRelatedWork W5689981 @default.
• W3013558407 hasRelatedWork W6100830 @default.
• W3013558407 hasRelatedWork W7996314 @default.
• W3013558407 hasRelatedWork W9199247 @default.
• W3013558407 hasRelatedWork W9573671 @default.
• W3013558407 isParatext "false" @default.
• W3013558407 isRetracted "false" @default.
• W3013558407 magId "3013558407" @default.
• W3013558407 workType "article" @default.